Elanco Animal Health (NYSE:ELAN) CEO Buys $478,500.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CEO Jeffrey Simmons acquired 22,000 shares of Elanco Animal Health stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the purchase, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elanco Animal Health Trading Up 2.0%

Shares of Elanco Animal Health stock traded up $0.43 on Monday, reaching $21.72. The company had a trading volume of 5,970,920 shares, compared to its average volume of 5,860,102. The firm has a market cap of $10.79 billion, a price-to-earnings ratio of 361.98, a P/E/G ratio of 2.89 and a beta of 1.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The firm’s 50-day moving average price is $21.73 and its two-hundred day moving average price is $18.10. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $23.70.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the company earned $0.13 earnings per share. Elanco Animal Health’s revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. SJS Investment Consulting Inc. lifted its holdings in shares of Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares during the period. Huntington National Bank increased its stake in shares of Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after acquiring an additional 951 shares during the period. Finally, First Horizon Advisors Inc. grew its holdings in Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after acquiring an additional 2,414 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. UBS Group upped their target price on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday, November 19th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus target price of $22.78.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.